Aminoguanidine and the effects of modified LDL on cultured retinal capillary cells

Investigative Ophthalmology and Visual Science

Volumn 41, Issue 5, 2000, Pages 1176-1180

  Lyons, Timothy J ^a   Li, Wei ^a   Wojciechowski, Barbara ^a   Wells Knecht, Mary C ^b   Wells Knecht, Kevin J ^b   Jenkins, Alicia J ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGUANIDINE; LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ARTICLE; CATTLE; CELL COUNT; CELL SURVIVAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG EFFECT; ENDOTHELIUM CELL; NONHUMAN; PRIORITY JOURNAL; RETINA CAPILLARY; RETINA CELL;

ANIMALS; CAPILLARIES; CATTLE; CELL COUNT; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; GLYCOSYLATION; GUANIDINES; LIPOPROTEINS, LDL; OXIDATION-REDUCTION; PERICYTES; RETINAL VESSELS;

EID: 0034126914     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Lyons TJ, Li W, Wells-Knecht MC, Jokl R. Toxicity of mildly modified low density lipoproteins to cultured retinal capillary endothelial cells and pericytes. Diabetes. 1994;43:1090-1095.
2. Hammes HP, Martin S, Federlin K, et al. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA. 1991;88:11555-11558.
3. Hammes H-P, Strodter D, Weiss A, et al. Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model. Diabetologia. 1995;38:656-660.
4. Panagiotopoulos S, O'Brien RC, Bucala R, et al. Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit. Atherosclerosis. 1998;136:125-131.
5. Soulis-Liparota T, Cooper M, Papazoglou D, et al. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes. 1991;40:1328-1334.
6. Cameron NE, Cotter MA, Dines K, Love A. Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin diabetic rats. Diabetologia. 1992;35:946-950.
7. Swamy-Mruthinti S, Green K, Abraham EC. Inhibition of cataracts in moderately diabetic rats by aminoguanidine. Exp Eye Res. 1996; 62:505-510.
8. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care. 1992;15:1835-1843.
9. Tilton RG, Chang K, Hasan KS, et al. Prevention of diabetic vascular dysfunction by guanidines: inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes. 1993; 42:221-232.
10. Lyons TJ, Jenkins AJ. Glycation, oxidation and lipoxidation in the development of the complications of diabetes mellitus: a carbonyl stress hypothesis. Diabetes Rev. 1997;5:365-391.
11. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic: new perspective on an old paradigm. Diabetes. 1999;48:1-9.
12. Ahmed MU, Thorpe SR, Baynes JW. Identification of carboxymethyllysine as a degradation product of fructoselysine in glycosylated proteins. J Biol Chem. 1986;261:4889-4894.
13. Chakravarthy U, Stitt AW, McNally J, et al. Nitric oxide synthase activity and expression in retinal capillary endothelial cells and pericytes. Curr Eye Res. 1995;14:285-294.
14. Bucala R, Makita Z, Vega G, et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA. 1994;91:9441-9445.
15. Lyons TJ, Klein RL, Baynes JW, et al. Stimulation of cholesteryl ester synthesis in human monocyte-derived macrophages by lipoproteins from type I diabetic subjects: the influence of non-enzymatic glycosylation of low-density lipoproteins. Diabetologia. 1987;30:916-923.
16. ∈-(carboxymethyl)-hydroxylysine in human skin collagen. Biochemistry. 1991;30:1205-1210.
17. Esterbauer H, Striel G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of low density lipoproteins. Free Radic Res Commun. 1989;6:67-75.
18. Jenkins AJ, Klein RL, Chassereau CN, et al. LDL from patients with well controlled IDDM is not more susceptible to in vitro oxidation. Diabetes. 1996;45:762-767.
19. Voyta JC, Via DP, Butterfield CF, Zetter BR. Identification and isolation of endothelial cells based on their increased uptake of acetylated-low density lipoprotein. J Biol Chem. 1984;99:2034-2040.
20. Requena JR, Vidal P, Cabezas-Cerrato J. Aminoguanidine inhibits protein browning without extensive Amadori carbonyl blocking. Diabetes Res Clin Pract. 1993;19:23-30.
21. Philis-Tsimikas A, Parthasarathy S, Picard S, et al. Aminoguanidine has both pro-oxidant and antioxidant activity toward LDL. Arterioscler Thromb Vasc Biol. 1995;15:367-376.
22. Lyons TJ, Li W, Jokl R. Effect of D-glucose on the viability of bovine retinal capillary pericytes and endothelial cells (Abstract). Diabetes. 1993;42(suppl 1):190A.
23. Colles SM, Irwin KC, Chisolm GM. Roles of multiple oxidized LDL lipids in cellular injury: dominance of 7 beta-hydroperoxycholesterol. J Lipid Res. 1996;37:2018-2028.
24. Witztum JL, Berliner JA. Oxidized phospholipids and isoprostanes in atherosclerosis. Curr Opin Lipidol. 1998;9:441-448.
25. Jenkins AJ, Li W, Moller K, et al. Pre-enrichment of modified LDL with α-tocopherol mitigates adverse effects on cultured retinal capillary cells. Curr Eye Res. 1999;19:137-145.
26. Lyons TJ, Li W, Gates D, et al. Effects of modified LDL on cultured retinal capillary cells: mechanisms of toxicity and mitigation by pre-enrichment with α-tocopherol (Abstract). Diabetologia. 1998; 41(suppl 1):A280.